Skip to main navigation Skip to search Skip to main content

Wegovy approved to treat severe fatty liver disease

Press/Media: Expert Comment

Description

Experts say the TGA’s provisional approval of the new indication could help slow disease progression, alongside other early intervention strategies.

Subject

Fatty liver

semaglutide

Period1 Apr 2026

Media contributions

1

Media contributions

  • TitleWegovy approved to treat severe fatty liver disease
    Degree of recognitionNational
    Media name/outletNewsGP
    Media typeWeb
    Country/TerritoryAustralia
    Date1/04/26
    DescriptionExperts say the TGA’s provisional approval of the new indication could help slow disease progression, alongside other early intervention strategies....
    Chair of RACGP Expert Committee – Quality Care, Professor Mark Morgan, stressed that GPs should be mindful of the cost barriers that come with Wegovy’s new indication.

    ‘Before rushing to prescribe these medicines to people with MASH there is a need to consider affordability until the PBS catches up to fund use of these medicines in line with TGA-approved indications,’ he said.

    There are also side effects to consider, such as nausea, diarrhoea, mental health deterioration, as well as the challenge of rebound weight gain.
    Producer/AuthorKaren Burge
    URLhttps://www1.racgp.org.au/newsgp/clinical/wegovy-approved-to-treat-severe-fatty-liver-diseas?utm_source=racgpnewsgpnewsletter&utm_campaign=newsgpedm&utm_medium=email
    PersonsMark Morgan